Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma LSE:VRP London Ordinary Share GB00B06GSH43 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.05p -1.56% 3.15p 3.00p 3.30p 3.30p 3.10p 3.30p 1,206,745.00 10:29:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -8.9 -0.7 - 80.83

Verona Pharma Share Discussion Threads

Showing 12551 to 12574 of 12575 messages
Chat Pages: 503  502  501  500  499  498  497  496  495  494  493  492  Older
DateSubjectAuthorDiscuss
18/1/2017
08:43
Tim.i know but play the game small investors always lose out to the money men.All well and good if the Sp opens @4 or 5 bucks.And not at the planned 2 bucks.
thebossman
18/1/2017
07:53
>>>bossman I suspect the main reason for the consolidation is to assist with the Nasdaq listing. Apparently US investors much prefer shares denominated in dollars rather than cents.
timbo003
18/1/2017
07:21
50 Of mine for 1 new share.Same old story then...
thebossman
11/1/2017
22:51
yes more professional website. I reckon this may be a very exciting first quarter. That's what my bank manager is hoping for anyhow.
shakin not stirred
10/1/2017
08:55
Thanks bewise2 A better focussed and more 'businesslike' website. I wonder if the anticipated IPO in the USA has prompted this revamp? Note also the London address is given which would also be more attractive to USA investors.
vasilis
09/1/2017
20:36
Vrp has a new website...take a look guys :)
bewise2
04/1/2017
17:25
It may simply be that she had to exercise her options upon leaving the company, as it may be a condition of holding the options that you are an employee? (I don't know if that's the case, but it's certainly a possibility.)
lord buffett
03/1/2017
13:43
lets hope she does not. Otherwise not looking too good for her confidence in RPL554
shakin not stirred
29/12/2016
18:49
Wouldn't be surprised if Kathy didn't cash in her 2m shares now she's gone.
ewads
21/12/2016
09:50
Having read the posts prior to there removal from VRP LSE board.It would suggest that your paraphrasing of the famous line from Casablanca might be very appropriate. No doubt see an uplift in share price in 2017. " of all the COPD lab jpoints in all the towns in all the world GSK walk into VRP or visa versa??
shakin not stirred
20/12/2016
10:11
Vasilis I hope you are correct in your paraphrase.
shakin not stirred
19/12/2016
13:58
Must be due at least 3 rns in New Year. With reference to CF trials. Kathys replacement. USA listing. But which order. Can think of another RNS but will wait and see. All have a fabulous Christmas and PROSPEROUS 2017 or 2018 if invested here.
shakin not stirred
19/12/2016
13:51
Let us hope that all our patents are water tight else Verona Pharma have just given a massive boost to GSK which would be quite disadvantageous for us investors. However the institutional investors I presume are fully aware of Kathy's move to GSK and seem unperturbed as no big sells and I have to presume they have an ear of the hierarchy in Verona?
shakin not stirred
16/12/2016
10:58
Good spot Vas (and Mol). Reassuring to know that RPL554 is definitely now on GSK's radar screen. I wonder who will replace Kathy at Verona?
timbo003
16/12/2016
09:38
Grateful to mol42 for picking this up on the II BB :- https://uk.linkedin.com/in/kathy-abbott-banner-236b061a As you can see, Kathy was with Verona for nearly 4 years in a number of different roles and was involved with the development of the new suspension formula of RPL554 as well as the IP filings and has now moved to GSK as from last month. Presumably GSK made her an 'offer she couldn't refuse', but more significantly for us is the fact that Kathy probably knows more about the new formulation of RPL554 than anyone else outside of Verona Pharma. However, whether or not her 'inside knowledge' of RPL554 was a factor or not in her getting her new job at GSK remains to be seen.
vasilis
08/12/2016
18:00
Whats the pros and cons of a USA float for shareholders?
francis55
02/12/2016
07:08
Friday 02 December, 2016 GlaxoSmithKline PLC Relvar Ellipta approved in Japan for COPD RNS Number : 7952Q GlaxoSmithKline PLC 02 December 2016
thebossman
23/11/2016
10:27
I hope the US listing goes somewhat better than it did for Motif Bio (MTFB), which was a disaster as far as the share price was concerned
timbo003
23/11/2016
10:13
Got to think that the US valuation will be a much higher one than a UK centric one -based on its potential. For various reasons many US funds prefer to buy US listed. Currency might be one factor.
meijiman
23/11/2016
09:47
Cracking RNS, onwards and upwards....everything moving into place nicely!
bewise2
23/11/2016
09:42
surely this shows that the team think they have a great product why wold you do this with the costs involved if it was to fail its clinicals ? discuss
oldvic
23/11/2016
09:30
RNS - Looking to float in the US next year.
phowdo
22/11/2016
09:43
Chippenham, UK - 22 November 2016: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading inhaled airways disease focused business, today announces that it has signed a US development and license agreement with Hikma Pharmaceuticals PLC ("Hikma") (through its wholly-owned subsidiary, West-Ward Pharmaceuticals) for Vectura's VR730 product. VR730 is a generic long acting beta-agonist (LABA) for the treatment of Asthma and COPD delivered using Vectura's proprietary dry powder inhalation technology and device. According to IMS, US sales of inhaled DPI and pMDI LABAs were approximately $150 million in 20151.
thebossman
21/11/2016
10:14
>>thanks Vas et al Another thought worth mentioning is that they are unlikely to get an Asthma indication for a product containing vilanterol (only COPD) as FDA really do have it in for LABAs for the treatment of Asthma.
timbo003
Chat Pages: 503  502  501  500  499  498  497  496  495  494  493  492  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170119 10:57:39